Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about treatment/resistant depression

Recent news which mentions treatment/resistant depression

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Tickers ATAI
Tags ATAI Health Care Srinivas Rao
From Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Tickers JNJ NEWS
Tags News TDR JNJ
From Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
Tickers NEWS
Tags Rob Conley News Beckley Psytech Ltd
From Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Tickers ATAI NEWS
Tags treatment/resistant depression Market News Cannabis
From Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Tickers CMPS
Tags CMPS Psychedelic/Assisted Therapies Management
From Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Tickers AWKNF CMPS
Tags Penny Stocks News severe alcohol use disorder
From Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Tickers ATAI
Tags Management Psychedelic/Assisted Therapies Psychedelics
From Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
Tickers CMPS
Tags Psilocybin program Benzinga Psychedelics
From Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
Tickers GHRS
Tags News Guidance GHRS
From Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
Tickers CMPS
Tags treatment/resistant depression Markets Cannabis
From Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
Tickers ATAI CMPS HTGC
Tags Penny Stocks HTGC ATAI
From Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Tickers CMPS NUMIF
Tags NUMIF News Cannabis
From Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
Tickers GHRS
Tags Guidance News GHRS
From Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Tags News Markets Market News
From Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
Tickers ATAI CMPS IGXT
Tags IGXT ATAI News
From Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Tickers CMPS
Tags Psychedelics Benzinga bipolar disorder
From Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
Tickers CMPS
Tags Guidance News clinical trials
From Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
Tickers CMPS
Tags Psychedelics Benzinga Psychedelic/Assisted Therapies
From Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
Tags Lusaris Therapeutics News Cannabis
From Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Tickers ATAI
Tags Market News Cannabis Markets
From Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
Tickers CMPS
Tags myPathfinder Dr/ Walter Kaye treatment/resistant depression
From Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
Tags News Psychology Markets
From Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
Tickers CMPS
Tags treatment/resistant depression Markets Compass Pathways
From Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
Tickers GHRS
Tags Sonoran desert toad Benzinga Small Business
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.